CT Surgeon | Resident | Medical Student | In the News
 
     

Abstract Submission

Quick Links










The Annual Meeting abstract submission deadline has passed.
Authors of accepted abstracts will be notified in mid-December.

Index

General Overview
Session/Presentation Categories
Basic Submission Overview
Abstract Submission Policies
Responsibilities of the Presenting Author
Abstract Acceptance/Rejection Notification
Authors’ Consent and Waiver of Claims
Abstract Withdrawal
ACCME Guidelines
Sample Abstract
Contact Information

General Overview

The AATS Program Committee follows a strict protocol in the selection process. Abstracts are blinded to authors’ names and institutions and graded by the Program Committee and ad hoc reviewers. The highest scoring abstracts are then reviewed in a second round by the Program Committee, again in a blinded fashion.

The Program Committee meets in early December to construct the scientific program based on these scores. The abstracts are then unblinded to assure a program balanced in authorship and institutional representation.

Below are the rules for submission, as well as some tips to help facilitate your abstract submission process. Good luck!


Return to Index

Session/Presentation Categories:

  • Regular Session: Select from among the following categories that which most accurately defines the field your abstract represents. This will determine program subcommittee assignments:

    ADULT CARDIAC: Clinical and translational studies pertaining to the selection, treatment and outcomes of patients with acquired cardiovascular conditions.
    CONGENITAL: Clinical and translational studies pertaining to the selection, treatment and outcomes of patients with congenital disorders of the heart, lungs and great vessels.
    ENDOVASCULAR/TRANSCATHETER VALVES: Clinical and translational studies pertaining to percutaneous, endovascular or transapical interventions to treat cardiovascular diseases.
    GENERAL THORACIC: Clinical and translational studies pertaining to the selection, treatment and outcomes of patients with benign and malignant conditions of the lungs, airways, mediastinum, diaphragm and chest wall.
  • Laboratory Research Forum: Appropriate studies include original basic science and laboratory animal experiments or translational research performed on tissue or blood obtained from patients. In contrast to the Lillehei Forum, presenters for the Research Forum Sessions are not limited to North American cardiothoracic and general surgery residents.
  • Emerging Technologies Forum: Presentations are focused on emerging technologies and techniques that would be of interest to cardiothoracic surgeons worldwide.
  • C. Walton Lillehei Resident Forum: This forum is limited to original work presented by residents in thoracic surgery and/or residents in general surgical training programs who are working in a cardiothoracic surgical laboratory or clinical rotation in North America. This forum is designed primarily for abstracts concerning basic science and laboratory animal experiments or translational research performed on tissue or blood obtained from patients. Rarely, clinical abstracts, when analyzed and presented by residents, would also be considered. The Cardiothoracic Residents Committee will evaluate these abstracts as a separate category to select eight abstracts for presentation. Each selected author will receive round-trip travel and accommodations for the duration of the annual meeting. Additionally, one presentation will be selected by the Cardiothoracic Residents Committee to receive the AATS Residents' Award of $5,000. Training Program Directors are urged to have residents participate in the Resident Forum session and must acknowledge that the material being presented is original work and that of the resident.
  • Other: This category will consist of presentations on subjects about which the submitter is uncertain about the proper category. Such topics might include surgical education and training, cardiothoracic quality assurance, cardiothoracic workforce issues or other broad programs that do not fit neatly into one of the other categories. These submissions will be classified and scored by members of the Program Committee based on similarities and associations with other abstracts.

Return to Index

Basic Submission Overview

  • Submission of an abstract constitutes a commitment by the author(s) to present the paper if accepted, and an exclusive, binding obligation to submit the manuscript only to the Journal of Thoracic and Cardiovascular Surgery (JTCVS)*. Please refer to the Journal link on the AATS website (also accessible through www.jtcvs.com or www.ctsnet.org) for more information. Papers must be submitted to the JTCVS electronically (http://www.editorialmanager.com/jtcvs/) before the start of the meeting (prior to presentation. The Editor requests that submission occur a month prior to the meeting to facilitate its review and, if accepted, earliest possible publication.

    *The requirement for manuscript submission to the JTCVS does not apply to abstracts selected for the Laboratory Research Forum sessions (Cardiac Surgery Forum or General Thoracic Surgery Forum) or the C. Walton Lillehei Resident Forum.
  • Abstracts containing identical or nearly identical data submitted from the same institution and/or authors will be disqualified and all authors and co-authors may face a two-year sanction.
  • Authors should not split data to create several abstracts from one study, clinical trial or experiment. If splitting is judged to have occurred, priority scores of all related abstracts will suffer, and abstracts may be disqualified.
  • Abstracts should clearly reflect the content of the completed paper.
  • Current contact information (including a working email address, phone and fax numbers) for the primary and senior authors must be entered; submitting authors will not be permitted to proceed until this information is provided.
  • Once submitted, abstract content can be edited until the submission deadline, October 4, 2011. After the deadline has passed, all content is considered FINAL and no changes can be made. Please proofread the abstract thoroughly before submitting or after editing. Should the abstract be accepted for presentation, it will be published as submitted/last edited.

Return to Index

Abstract Submission Policies

VIEW SAMPLE ABSTRACT

  • Please note: Videos and PowerPoints are not accepted as part of abstract submissions for the 2011 AATS Annual Meeting.
  • The text of your abstract must be less than 2,500 characters including spaces for the text of your abstract submission (title, authors, institutions and one table or one image will not be counted). You may use one table or one figure within your abstract.
  • If an author's name appears on more than one abstract, it must be identical on each abstract. If an author has more than one abstract accepted for presentation, he/she may only present one paper personally and must assign an alternate presenter to the second abstract.
  • The abstract should have a short, concise title which indicates the nature of the study. The title or body of the abstract must NOT include product names in order to comply with the Standards of Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME) which accredits the AATS. Abstracts that reference product names in either the title or body may be disqualified.
  • In order to maintain anonymity, neither the title nor the abstract text should identify the institution and/or author(s) in any way (i.e. “1000 Case Study at State General” is NOT an acceptable title).
  • The abstract title should NOT use abbreviations which are not commonly accepted within the cardiothoracic surgical literature. Commonly accepted abbreviations within the cardiothoracic surgical literature will be accepted, i.e., CABG, FEV1, GERD, CPR. However, other medical acronyms, i.e., bronchiolitis obliterans syndrome (BOS) should be first spelled out.
  • All abstracts must be structured using the following section headings or they will not be considered. The labels must be submitted in bold font:
    • OBJECTIVE(S) – The hypothesis tested or the rationale or purpose of the study.
    • METHODS – Details of the study design or protocol.
    • RESULTS - Results of the study with appropriate statistical inferences.
    • CONCLUSIONS – Clinical importance and potential significance of your findings.
  • When percentages are used, the absolute numbers from which the fractions are derived must also be stated.
  • Use generic, not commercial, names for all therapeutic agents.

Return to Index

Responsibility of the Presenting Author

  • The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified in the contact information provided during the online submission process.
  • The presenting author must be one of the co-authors listed on the submitted abstract.

Return to Index

Abstract Acceptance/Rejection Notification Decisions of the Program Committee will be made known to all Presenting Authors by email after December 17, 2010. It is the responsibility of the Presenting Author to notify all co-authors of the Program Committee’s decision.


Return to Index

Authors’ Consent & Waiver of Claims

  • Each author agrees that they have read and consent to all rules and regulations as outlined, pertaining to submission of abstracts. It is the responsibility of the authors to be in accordance with these rules and regulations during all parts of, but not limited to, abstract submission and review.
  • Upon submission, authors waive any and all claims against the AATS and any Reviewer and/or Program Committee member pertaining to, but not limited to, the abstract submission and review process.
  • If the presenting author has been trained or utilized by a commercial entity or its agents as a speaker (e.g. participation in the Speaker’s Bureau) for any commercial interest, the promotional aspects of that work must not be included in the presentation in any way.
  • Presenting authors must act in full accordance with HIPAA Research Policies. Any and all abstracts and presentation materials must follow these guidelines.
  • EMBARGO POLICY: Submission, presentation or publication of any submitted abstract and/or its contained information by any of its authors to any other entity outside of the AATS 91st Annual Meeting prior to notification of abstract selection by the Program Committee in December 2010 is prohibited. The work MUST NOT have been submitted, presented or published elsewhere prior to submission to the AATS 91st Annual Meeting in May 2011, as well. Once an abstract is accepted, it is prohibited from being submitted, presented or published elsewhere prior to its presentation at the AATS 91st Annual Meeting. Failure to follow this policy will jeopardize the eligibility of all authors to submit abstracts to future AATS meetings and/or submit manuscripts for publication in the JTCVS in future years.

Return to Index

Abstract Withdrawal

Requests for withdrawal of an abstract must be received in writing no later than November 30, 2010 and must state the reason for withdrawal.

Withdrawal requests made after November 30, 2010 may result in a two-year sanction of the submitting author and all co-authors.


Return to Index

ACCME Guidelines

  • Based upon ACCME criteria, after entering abstract text, authors will be asked three questions for which responses are strongly encouraged but not mandatory. Please contact meetings@aats.org with questions.

    • What quality gap (limitation or problem) in the practice of cardiothoracic surgery does this research address?
    • How does this project change surgeon competence or improve patient outcomes?
    • Please indicate which of the following ACGME Competencies this abstract addresses. (Medical Knowledge, Patient Care, Interpersonal and Communication Skills, Professionalism, Practice-based Learning and Improvement and Systems-based Practice)
  • In accordance with ACCME’s Standards for Commercial Support, The American Association for Thoracic Surgery, as the accredited CME provider of this activity, follows a strict disclosure process to ensure that anyone who is in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest as it pertains to the content of the presentation. The goal of this process is not to exclude authors who have financial conflicts, but to manage these conflicts. The submitting author will complete a Disclosure Form and Content Validation Form. All co-authors will receive an email directing them to the website to complete the Disclosure Form and Content Validation Form which all authors and co-authors MUST complete.

Return to Index

Sample Abstract

Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Gail E. Darling1, Mark S. Allen2, Paul Decker3, Karla V. Ballman3, Rodney J. Landreneau4, Robert J. McKenna5, David R. Jones7, Richard I. Inculet8, Valerie W. Rusch9, Joe B. Putnam6
1 Surgery, University of Toronto, Toronto, ON, Canada; 2 Surgery, Mayo Clinic, Rochester, MN; 3 Biostatistics, Mayo Clinic, Rochester, MN; 4 Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; 5 Thoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; 6 Thoracic Surgery, Vanderbilt University, Memphis, TN; 7 Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA; 8 Surgery, University of Western Ontario, London, ON, Canada; 9 Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.


Objective: To evaluate whether mediastinal lymph node dissection (MLND) improves overall survival compared to mediastinal lymph node sampling (MLNS) in patients undergoing pulmonary resection for N0 or non-hilar N1, T1 or T2 NSCLC.
Methods: : Patients with proven NSCLC underwent sampling of lymph node stations 2R, 4R, 7 and 10R for right sided tumors; and 5, 6, 7 and 10L for left sided tumors. If these lymph node stations were negative for malignancy, patients were randomized to no further lymph node resection (MLNS) or complete MLND. All surgeons were required to adhere to the technique described in written instructions and demonstrated in an approved instructional video. Following surgery, patients were followed for a minimum of 5 years.
Results: A total of 1,111 patients were randomized (555 MLNS and 556 MLND). After final eligibility review, 1,023 (498 MLNS and 525 MLND) patients were classified as eligible/evaluable. There were no significant differences between the two groups in terms of gender, race, age or ECOG performance status. The right upper lobe was the most common tumor location (MLNS: 213 vs MLND: 205) and adenocarcinoma was the most common histologic type in both arms (MLNS: 210 vs MLND: 235). There was no significant difference between the two arms in terms of type or extent of resection, stage, length of stay, morbidity or mortality. In the MLND group 20 patients (3.8%) were found to have occult N2 disease in the lymphadenectomy specimen. At a median follow-up of 6.3 years, 431 (42.1%) patients have died: 214 (42.9%) in the MLNS arm and 217 (41.3%) in the MLND arm. The median survival was 8.1 years (MLNS) versus 8.5 (MLND) (p=0.531). There were 493 recurrences including deaths: 54 local; 73 regional; and 224 distant. The median time to recurrence was 5.7 years in the MLNS group (243 recurrences; 24 local; 42 regional; and 110 distant) versus 6.1 years in the MLND group (250 recurrences; 30 local; 31 regional; and 114 distant) (p=0.655). There also was no difference for local (p=0.527) or regional recurrence (p=0.126) between the two groups.
Conclusion: MLND does not improve survival in patients with early stage NSCLC when a thorough preresection sampling of the mediastinal lymph nodes is negative. MLND also does not decrease the incidence of local or distant recurrences. These results are not generalizable to higher stage tumors.

Return to Abstract Submission Policies

Return to Index

Contact Information

For further information on submitting an abstract for consideration,
please contact:
American Association for Thoracic Surgery
900 Cummings Center
Suite 221-U, Beverly, MA, USA 01915
Telephone: +1 (978) 927-8330
Fax: + 1 (978) 524-8890
E-mail: meetings@aats.org

 

 
We Model Excellence
Follow AATS on YouTube Follow AATS on Facebook
Copyright © 2014 American Association for Thoracic Surgery
All rights reserved. IMPORTANT REMINDER: The preceding information is intended only to provide general guidance and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult a doctor about any specific medical problem or question.